Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

5.3K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.3K
DNA-only Transposons02:57

DNA-only Transposons

17.3K
DNA-only transposons are called autonomous transposons since they code for the enzyme transposase that is required for the transposition mechanism. Insertion of transposons can alter gene functions in multiple ways. They can mutate the gene, alter gene expression by introducing a novel promoter or insulator sequence, introduce new splice sites, and change the mRNA transcripts produced, or remodel chromatin structure.
The donor site from where the transposon is excised is either degraded or...
17.3K
Overview of Transposition and Recombination02:13

Overview of Transposition and Recombination

19.1K
Transposons make up a significant part of genomes of various organisms. Therefore, it is believed that transposition played a major evolutionary role in speciation by changing genome sizes and modifying gene expression patterns. For example, in bacteria, transposition can lead to conferring antibiotic resistance. Movement of transposable elements within the genetic pool of pathogenic bacteria can aid in transfer of antibiotic-resistant genetic elements. In eukaryotes, transposons can carry out...
19.1K
What is Cell Signaling?02:03

What is Cell Signaling?

129.9K
Despite the protective membrane that separates a cell from the environment, cells need the ability to detect and respond to environmental changes. Additionally, cells often need to communicate with one another. Unicellular and multicellular organisms use a variety of cell signaling mechanisms to communicate to respond to the environment.
129.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

Blood cancer discovery·2026
Same author

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.

Leukemia·2026
Same author

Impact of baseline osseous involvement on outcomes in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia.

Blood neoplasia·2026
Same author

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Blood cancer journal·2026
Same author

Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Jan 25, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.0K

Targeting BTK in CLL: Beyond Ibrutinib.

David A Bond1, Jennifer A Woyach2

  • 1Department of Internal Medicine, Division of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, 445D Wiseman Hall CCC, 410 W 12th Ave, Columbus, OH, 43210, USA.

Current Hematologic Malignancy Reports
|April 28, 2019
PubMed
Summary

New Bruton's tyrosine kinase inhibitors (BTKi) offer improved selectivity and overcome resistance in chronic lymphocytic leukemia (CLL). Research is ongoing to define their role in CLL treatment.

Keywords:
AcalabrutinibB cell receptorTirabrutinibZanubrutinib

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

18.0K
Technique to Target Microinjection to the Developing Xenopus Kidney
11:29

Technique to Target Microinjection to the Developing Xenopus Kidney

Published on: May 3, 2016

12.0K

Related Experiment Videos

Last Updated: Jan 25, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.0K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

18.0K
Technique to Target Microinjection to the Developing Xenopus Kidney
11:29

Technique to Target Microinjection to the Developing Xenopus Kidney

Published on: May 3, 2016

12.0K

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Ibrutinib, a Bruton's tyrosine kinase inhibitor (BTKi), has transformed chronic lymphocytic leukemia (CLL) treatment.
  • Limitations of ibrutinib include off-target toxicities and acquired resistance.
  • Newer BTKi agents are being developed to address these challenges.

Purpose of the Study:

  • To review emerging data on alternative Bruton's tyrosine kinase inhibitors (BTKi) for chronic lymphocytic leukemia (CLL).
  • To discuss the efficacy and toxicity profiles of next-generation and reversible BTKi.
  • To outline the ongoing clinical trials and future directions for BTKi in CLL therapy.

Main Methods:

  • Literature review of recent studies on alternative Bruton's tyrosine kinase inhibitors (BTKi).
  • Analysis of data from early-phase clinical trials evaluating new BTKi agents.
  • Discussion of mechanisms of resistance and strategies to overcome them.

Main Results:

  • Second-generation BTKi (acalabrutinib, zanubrutinib, tirabrutinib) offer greater BTK selectivity, potentially reducing off-target toxicities.
  • Reversible BTKi (vecabrutinib, LOXO-305) and non-selective reversible BTKi (ARQ-531) show activity against resistance mutations (C481S, PLCG2 mutations).
  • Ongoing trials will establish the clinical efficacy and toxicity of these agents.

Conclusions:

  • Alternative Bruton's tyrosine kinase inhibitors (BTKi) represent a promising advancement in chronic lymphocytic leukemia (CLL) treatment.
  • These agents may offer improved safety profiles and overcome resistance mechanisms.
  • Further clinical trials are essential to determine the optimal role of new BTKi in CLL management, as monotherapy or combination therapy.